Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Retained Earnings (2016 - 2017)

Historic Retained Earnings for Ascendis Pharma A (ASND) over the last 6 years, with Q3 2017 value amounting to $208.3 million.

  • Ascendis Pharma A's Retained Earnings rose 21186.72% to $208.3 million in Q3 2017 from the same period last year, while for Sep 2017 it was $208.3 million, marking a year-over-year increase of 21186.72%. This contributed to the annual value of $172.0 million for FY2016, which is 268.32% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Retained Earnings of $208.3 million as of Q3 2017, which was up 21186.72% from $114.4 million recorded in Q2 2017.
  • In the past 5 years, Ascendis Pharma A's Retained Earnings registered a high of $208.3 million during Q3 2017, and its lowest value of $2.9 million during Q4 2013.
  • Its 5-year average for Retained Earnings is $119.3 million, with a median of $137.1 million in 2015.
  • Per our database at Business Quant, Ascendis Pharma A's Retained Earnings surged by 160222.25% in 2014 and then plummeted by 5127.98% in 2016.
  • Over the past 5 years, Ascendis Pharma A's Retained Earnings (Quarter) stood at $2.9 million in 2013, then surged by 1602.22% to $49.4 million in 2014, then soared by 238.69% to $167.5 million in 2015, then rose by 2.68% to $172.0 million in 2016, then increased by 21.16% to $208.3 million in 2017.
  • Its Retained Earnings stands at $208.3 million for Q3 2017, versus $114.4 million for Q2 2017 and $143.6 million for Q1 2017.